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The human alloantlgen system Bak”‘h 1s associated with a Ile’” + Ser replacement on platelet glycoprotem IIb, the u-subunit of the mtegrin receptor 
for fibrmogen (GPIIblIIIa) Recent immunological studies indicate that sialylated oligosaccharide chain(s) are also lmphcated m expression of the 
Bak” determmant. Here we show that the GPIIb fragment 704856 contams the whole Bak” epitope, and that chemical cleavage of a single O-linked 
ohgosaccharlde cham wlthin this GPIIb domam correlates with the loss of Its ant]-Bak” antlbodies bindmg ablhty. Se? has identified as the 
0glycosylatlon site Therefore. our results show that the Se? modification 1s responsible for the expression of the GPlIb-specific Bak” alloantlgen, 
and provide thus a hnk between the molecular biology and the lmmunologlc observations 
Platelet GPIIb/IIIa complex: Alloantigen: Bak”. O-Glycosylatlon 
1. INTRODUCTION 
Human glycoprotein (GP) IIb/IIIa complex, a Ca”- 
dependent heterodimer, is the major integrin receptor of 
the platelet membrane. It functions in adhesive interac- 
tions like platelet adhesion to the subendothelium and 
platelet aggregation. by serving on resting platelets as 
a low affinity adhesion receptor for surface-coated fi- 
brinogen, and upon platelet activation as the inducible 
receptor for soluble fibrinogen and other adhesive 
plasma proteins [l-3]. Besides its central role in normal 
hemostasis, GPIIb/IIIa (integrin a1”b3) bears a number 
of clinically important alloantigenic determinants that 
are implicated in the development of immunopathologic 
syndromes, such as posttransfusion purpura (PTP) and 
neonatal alloimmune thrombocytopenic purpura 
(NATP), due to platelet alloantigen incompatibility in 
recipients of blood transfusions (platelet transfusion 
refractoriness, PTR) and to maternal sensitization to 
paternal antigens on fetal platelets during pregnancy, 
respectively [4]. To date, six different alloantigen sys- 
tems have been localized to the GPIIb/IIIa complex. 
and the molecular basis of these polymorphisms have 
been solved at the molecular genetic level. Thus, the 
amino acid substitutions within the mature GPIIIa pol- 
ypeptide Leu33 + Pro [5], ArglJ3 -+ Gln [6], Pro”“’ + 
Ala [7], ArgJ8’ -+ Gln [8], and Arg636 + Cys [9] are pri- 
Correspondence address J.J. Calvete, Instltut fiir Reproduktlonsme- 
dizm. Tlerrirztliche Hochschule Hannover, Bhnteweg 15. 30559 Han- 
nover, Federal Republic of Germany. Fax: (49) (511) 953-8504. 
marily responsible for the formation of the PLA”’ 
(= ZW”‘b, HPA-1). Pendb (= Yukb’“. HPA-4), MO, CA/ 
TU, and Sr(a) alloantigen systems, respectively. On the 
other hand, the Bak”‘h (= Lekdih. HPA-3) system has 
been correlated with an Ile/Ser polymorphism at residue 
843 of the heavy chain of glycoprotein IIb [lo]. Serolog- 
ical data demonstrate that all GPIIb/IIIa alloantigens 
so far studied are diallelic systems showing a codomi- 
nant Mendelian inheritance pattern, though the pheno- 
type frequency of the different alloantigens on GPIIb/ 
IIIa varies within the human gene pool [4,11]. 
Unlike other single amino acid replacements resulting 
in dysfunctional GPIIb/IIIa complexes and conse- 
quently in platelet Glanzmann thrombasthenic pheno- 
types (i.e. Asp”’ -+ Tyr [12]; Arg213 + Gln [13] or Trp 
[ 141; Ser75’ + Pro [15] within GPIIIa. and Gly”’ + Asp 
[ 161 and Ser”j -+ Arg [ 171 within GPIIb), there does not 
appear to be any notable functional difference related 
to GPIIb/IIIa alloantigen phenotype [4]. 
Interestingly. the PLA and Sr(a) alloantigen stability 
is maintained by the native disulphide bond pattern of 
GPIIIa [18,19]. Similarly, Pen epitopes are dependent 
upon proper folding of the mature GPIIIa polypeptide 
chain [6]. The Bak determinants, on the other hand, do 
not depend on the presence of intact protein structure 
[20] but require posttranslational processing of pro- 
GPIIb (both carbohydrate modification and cleavage 
into heavy and light chains), in addition to the amino 
acid difference Ile843 + Ser, for efficient epitope expres- 
sion [21]. Moreover. both Bak” (HPA-3a) and Bak’ 
(HPA-3b) are sensitive to removal of sialic acid [21,22]. 
Here. we report the localization of an O-glycosylated 
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serine at the C-terminal end of the GPIIb heavy chain 
implicated in expression of the Bak alloantigen system. 
2. MATERIALS AND METHODS 
Anti-Bak” antlserum was kindly donated by Dr. Nordhagen (Na- 
tional Institute of Public Health, Oslo, Norway) and was employed 
without further purification, at a 1:5 (v/v) dilution in 20 mM phos- 
phate. 150 mM NaCI, pH 7.4 (PBS). 
Glycoprotein IIbH (the heavy cham of GPIIb) was obtained as 
previously described [23] using purified GPIIblIIIa [24] as the imtial 
material. 
Chemical degradation of GPIIbH with cyanogen bromide (CNBr) 
and size-exclusion and/or reverse-phase chromatographic lsolatlon of 
the resulting fragments were done as previously described m detail 
WI. 
SDS-gel electrophoresis was performed following [26], and electro- 
blotting onto mtrocellulose sheets was done using the method of Tow- 
bin et al. [27]. As second antibody a goat anti-(total) human Ig. 
peroxidase-conjugated antiserum (Sigma) was employed at a 1 : 2000 
(v/v) dilution in PBS. After washing with 20 mM Tris-HCI, 0.5 M 
NaCI, pH 7.4 (TBS), the blots were developed with TBS containing 
20% (v/v) methanol. 1 mg/ml 4-chloro-1-naphtol (BioRad) and 0.1 
PI/ml HZOz. 
Removal of O-linked carbohydrates from the 19 kDa C-terminal 
CNBr-fragment of GPIIbH was accomplished by alkaline B-ehmma- 
tion. To this end, the lyophilized polypeptide was resuspended at 1 
mg/ml m 5 mM NaOH, and then incubated for 24 h at 37°C in a 
toluene atmosphere [2X]. Thereafter, the peptide was extensively dyal- 
ized against deionized (Mdli-Q) water. lyophihzed, and stored at 
-20°C until use. 
Amino acid and ammo sugar analyses were done with a Biotronik 
LC5001 analyzer after hydrolysis at 110°C m 6 N HCl for 24 h and 
4 N HCI for 4 h, respectively. 
For proteolytic degradation isolated GPlIbH or its 19 kDa CNBr- 
derived fragment (5 mg/ml in 100 mM Tris-HCI. 2 mM CaC&. pH 7.8) 
were incubated overnight at 37°C either with trypsin, chymotrypsm, 
endo Lys-C protemase, or endo Glu-C protemase (Boehringer 
Mannheim) at an enzyme:substrate ratio of 1:lOO (w/w). After block- 
ing the enzyme activity with a 25 molar excess of phenylmeth- 
ylsulphonyl fluoride (PMSF) over enzyme concentration, the diges- 
tion mixtures were tested for their ability to bmd anti-Bak” antlbodies 
by competitive enzyme-linked immunosorbent assay (ELISA) as pre- 
viously described [29.30]. 
Tryptlc peptldes were purified by reverse-phase HPLC using a Li- 
chrospher RP-100 (Merck) Cl 8 column (25 x 0.4 cm, 5 pm particle 
size) eluted at 1 ml/min with a linear stepwise gradient of 0.1% (v/v) 
trlfluoroacetic acid in (A) water and(B) acetonitrile (lsocratically ( 10% 
B) for 5 min. followed by 1040% B m 90 min). The isolated peptides 
were characterized by amino acid and amino sugar analysis and N- 
terminal sequencing (using either a Beckman 890C or an Applied 
Biosystems 473A sequencer following the manufacturers instructions). 
3. RESULTS AND DISCUSSION 
In order to investigate the structural requirements for 
expression of the Bak” (HPA-3a) alloantigen on human 
platelet glycoprotein IIb, the isolated, reduced and car- 
boxymethylated GPIIbH was degraded with cyanogen 
bromide, the fragments separated by SDS-gel electro- 
phoresis, blotted onto nitrocellulose sheets and probed 
with and anti-Bak” antiserum. Fig. 1 (lane b) shows that 
only a 19 kDa electrophoretic band was recognized by 
the antiserum. This band contained, however, two deg- 
radation products (GPIIbH 315489 and 704-856) [25] 
kDa 
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Fig. 1. Detection by immunoblotting analysis of anti-Bak” binding 
activity. (Lane a) Electrophoretic control of the mixture of cyanogen 
bromide fragments obtained from reduced and carboxymethylated 
GPIIb. (Lane b) Binding of anti-Bak” antibodies to the sample shown 
m (a). (Lane c) Binding of anti-Bak” antiserum to HPLC isolated 
GPIIbH 704856 fragment. (Lane d) No anti-Bay binding to isolated 
fragment 3 15489 was observed. The numbers at the left side Indicate 
the apparent molecular mass of the major fragments m kllodaltons 
(kDa). 
but after separation by size-exclusion and reverse-phase 
chromatography [25,31] only the C-terminal fragment 
of GPIIbH retained the anti-Bak” binding activity (Fig. 
1 lane c). Fig. 1, lane d, shows that no anti-Bak” binding 
to GPIIbH 315-489 could be detected. Moreover, the 
fragment GPIIbH 704856, but not peptide 315489, 
competed quantitatively with intact GPIIb for anti- 
Bak” binding in an ELISA system (Fig. 2). In addition, 
enzymatic degradation of the 704-856 GPIIbH pol- 
ypeptide with either trypsin, chymotrypsin, endopro- 
teinase Lys-C or endoproteinase Glu-C did not affect 
antiserum recognition activity (Fig. 2), indicating that 
neither accessible basic amino acid side chains nor 
acidic or aromatic residues are involved in formation of 
the Bak” epitope. 
Amino sugar and amino acid analyses of the isolated 
19 kDa GPIIbH 704856 fragment revealed the pres- 
ence of 0.92 mol galactosamine/mol peptide, suggesting 
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Fig 2. DetectIon by compelitivr enzyme-hnked lmmunosorbent assay 
(ELISA) of anti-Bak” bmdmg actwty m reduced and carboxymethyl- 
ated GPlIbH (:J): HPLC-isolated 19 kDa cyanogen bromide fragment 
GPlIbH 704856 (0). cyanogen bromide fragments of GPIIb I-285: 
286 -314: 3 15489,490~549: 550-580;58 I 635,636 660: 661- 693: and 
694-703 (w). Isolated as described [15]. For slmpllclty only a curve 1s 
shown; mixture of tryptic or endoproteinase Lys-C peptides from 
GPIIbH 704-856 (0): mixture ofendoprotemase Glu-C from GPlIbH 
704-856 (x). mixture of chymotryptlc peptldes of GPIIbH 703-856 
(+); reverse-phase HPLC purllied GPIIbH fragment 704- 856 after 
deglqcosqlation by alkaline /J-ehminatlon (3). 
the existence of a single O-linked carbohydrate chain 
attached to any of the 1.5 serine or 2 theonine residues 
within the C-terminal part of GPIIbH. To test whether 
this oligosaccharide is actually involved in expression of 
the Bak” determinant, the GPlIbH 704-856 fragment 
was subjected to chemical deglycosylation by alkaline 
p-elimination. The degree of deglycosylation was appar- 
ently complete. as determined by amino acid and amino 
sugar analyses after purification of the NaOH-treated 
fragment by reverse-phase HPLC. When this peptide 
was tested, it did only show a very decreased anti-Bak” 
binding activity (Fig. 2; 0). The epitopes recognized by 
monoclonal antibodies MO? (GPIIbH’“’ 8-13) and M, 
(GPIIbH”59 857 ) [29] (data not shown) were not de- 
stroyed during the deglycosylation process, however. 
This strongly supports the hypothesis that the loss of the 
Bak” epitope was due to carbohydrate removal rather 
than to polypeptide damage. This conclusion agrees 
with recent reports showing that Bak” and Bakb epitope 
expression are sensitive to removal of sialic acid [?I ,221. 
In addition, our study demonstrates that the carbohy- 
drate implicated in Bak” determinant formation corre- 
sponds to an O-linked chain. and that this oligosac- 
charide is located within the C-terminal domain of 
GPIIbH. 
To further localize the O-linked carbohydrate chain 
within the GPIIbH 704-856 stretch, the 19 kDa peptide 
was degraded with trypsin or chymotrypsin. Fig. 3 
shows the HPLC isolation of the tryptic peptides puri- 
fied by reverse-phase HPLC and characterized by N- 
terminal sequencing (Table I) and amino acid and 
amino sugar analyses. As a whole. the tryptic peptides 
recovered from the Cl 8 column contained the complete 
amino acid sequence of the GPIIbH 704856 fragment 
except the dipeptide Ser”‘-Lys”(‘. Amino sugar analy- 
ses of this set of peptides revealed the presence of 0.8 
mol/mol peptide in peptide R5 only. On the other hand, 
the missing tryptic dipeptide was found within the not 
glycosylated chymotryptic fragment 720-737 (Table I). 
This result corroborated our previous conclusion that 
the 19 kDa fragment may contain a single oligosac- 
charide chain and further localized its position within 
the very C-terminal portion of GPIIbH. Peptide R5 
contains 2 serine residues and thus two potential glyco- 
sylation points. N-terminal sequencing analysis yielded 
the amino acid sequence: Va1837-Asp-Trp-Gly-Leu-Pro- 
Ile-Pro-Ser-Pro-Xaa-Pro-Ile-His-Pro-Ala . . . . indicating 
therefore that Se?’ but not SersJ5 is the modified resi- 
due. Since there are only three intervening residues be- 
tween position 843, whose polymorphism Ile/Ser has 
been correlated with expression of the Bakdib alloanti- 
gen system [I 01, and the glycosylated serine. the simplest 
explanation for their participation in Bak” epitope for- 
mation is that both residues will most probably occupy 
part of the -750 A’ antigen surface area that usually an 
antibody recognizes. 
Table I 
Characterization by N-termmal sequence analysis of the tryptlc pep- 
tides isolated m Fig. 3 
Peptlde N-termmal sequence Positlon 
Tl AEAQVELR 744-75 1 
T7 NSQNPNSK 717-734 
T3 EQNSLDSW 769-776 
T3 EQNSLDSWGPK 769-779 
T5 VDWGLPI PSPXPI H 837-856 
T6 I VLLDVPVR 735-743 
T7 GNS FPAS LVVAA 752-768 
T8 LVSVGNLEEAG 704-714 
T9 VEHTYELHNN 780-836 
C QLQI RS KNS QNPN 710-737 
Ammo acid sequences are m the standard one-letter code. N-termmal 
sequence of a selected chymotryptlc peptide (C) 1s also shoun. 
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FIN. 3. Isolation by reverse-phase HPLC of trypttc peptides (T-) of reduced and carboxymethylated GPIIbH 704856 For tdentification of each 
peak see Table I. 
In a previous paper [25] we reported that anti-GPIIb 
monocional antibody M5 preferentially recognized 
Bak” typified platelets. The M5 epitope has been located 
within the GPIIbH 550-558 polypeptide stretch, how- 
ever 1291. Whether this region of GPIIb is spatially prox- 
imal to the Bak” epitope within the quaternary structure 
of the GPIIblIIIa complex needs further detailed inves- 
tigation. 
The structure of the oligosaccharide chain implicated 
in Bak” formation remains to be established. It is also 
not clear whether the extra serine residue within the 
Bakb determinant is glycosylated. This issues are cur- 
rently being investigated in our laboratories. 
The C-terminal domain of the heavy chain of GPIIb 
represents avery interesting region. It contains a neoep- 
itope, GPIIbHR4’-856, recognized by monoclonal anti- 
body PMI- 1, originally selected on the basis of its ability 
to block platelet adhesion to collagen 1321. This epitope 
is fully suppressed at physiological calcium ion concen- 
tration but results fully available upon receptor occu- 
pancy [33]. The ligand-induced binding site (LIBS) de- 
fined by the PMI-1 epitope is flanked by permanently 
surface-exposed regions recognized by monocional an- 
tibodies M3 (GPIIbH*49-~~6) and MC? (GPIIbHs”7-KJ3) 
[29]. Remarkably, a single chymotryptic cleavage at 
GPIIbH PheYz7 or Trp839 releases the C-terminal peptide 
of GPIIbH and correlates with acquisition of perma- 
nently available fibrinogen binding sites [34]. Our find- 
ing that Ser 847 is glycosylated further indicates that this 
residue may be fully solvent accessible. Moreover, the 
region 842-851 is a proiine-rich polypeptide for which 
a proline-based helix or a multiple turn conformation 
is predicted. If this were the case, then positions 843 and 
847 would most probably reside on the surface-exposed 
face of the helix-like conformation, while the residues 
involved in expression of the PMI-I determinant will 
occupy the hidden part of the structure. This suggestive 
hypothesis deserves further detailed investigation. 
AcX-nou,irdgenlenrs Thts work was supported m part by the Action 
especial CSIC 630/00/07~ (J J.C.). 
REFERENCES 
111 
121 
131 
[41 
[51 
[61 
[71 
I81 
191 
UOI 
1111 
r121 
1131 
U41 
Phillips, D R , Charo. I.F. and Scarborough, R.M. (1991) Cell 65, 
359-36’ 
Plow. E F.. D’Souza, S E. and Ginsberg, M.H. (1992) J. Lab. 
Clin. Med. 120, 198204. 
Calvete, J.J. (1993) m. Adhesion Molecules (Mihich, E. and Hem- 
ler, M.E., eds.) Plenum Press, New Yark. pp. 63-91 
Kumcki. T.J. and Newman, P.J. (1992) Blood 80. 13861404 
Newman. P.J., Derbes. RS and Aster, R.H. (1989) J. Chn In- 
vest. 83, 1778-1781. 
Wang, R . Furihata, K., McFarland. J.G., Friedman, K., Aster, 
R.H. and Newman, P.J. (1992) J. Clin. Invest. 90, 20387043. 
Kugpers, R.W A.M.. Simsek, S , Faber. N.M.. Goldschmeding. 
R., van Wermerkerken. R.K.V and von dem Borne, A E.G.Kr. 
(1993) Blood 81, 70-76. 
Wang, R., McFarland. J.G , Kekomaki, R and Newman. P.J. 
(1992) Circulation 86, abstr. 2712. 
Santoso, S , Newman, P.J., Kalb, R., Kroll, H., Walka, M.. 
Kiefel, V. and Mueller-Eckhardt, C. (1992) Blood 80, abstr. 503. 
Lyman. S., Aster, R.H.. Visentin, G.P. and Newman, P.J. (1990) 
Blood 75. 2343.-2348. 
Newman. P.J. (1991) Thromb. Hacmost. 66, Ill--l18 
Loftus, J.C., O‘Toole. T.E.. Plow, E.F., Glass, A.. Frelmger III. 
A.L. and Gmsberg, M H (1990) Science 249. 915-918. 
Bajt. M.L., Gmsberg, M.H., Frehnger III. A.L.. Berndt, M.C. 
and Loftus, J.C. (1992) J. Biol. Chem. 267, 37893794. 
Lanza. F.. Stterle, A., Fournier. D., Morales. M., Andre, G.. 
33 
Volume 328, number 1.2 FEBS LETTERS August 1993 
Nurden. A. and Cazenave. J.-P. (1992) J Chn Invest. 89. 19955 [24] Rivas. G.A.. Calvete. J.J. and GonzBlez-Rodriguez, J. (1991) 
2004. Prot Express. Purif. 2. 248-255 
[15] Chen. Y-P. DJaffar. I.. Pidard, D , Steiner. B., Cieutat. A-M.. 
Caen. J.P. and Rosa, J.-P.(1992) Proc. Natl. Acad. Sci. USA 89. 
10169%10173. 
[16] Wilcox. D.A.. Wautler. J.-L.. Pidard. D. and Newman. PJ. 
(1992) Circulation 86. abstr. 2713 
[17] Tarantmo, M.D. and Nugent. D.J. (1992) Blood 80. abstr. 500 
[IS] Kumckl. T.J. and Aster. R.H. (1979) Mol Immunol. 16,353-360 
[19] Santoso, S. and Mueller-Eckardt (1992) personal commumca- 
tlon. 
[25] Calvete, J.J., Alvarez. M V.. Rlvas. G.. Hew, C.-L., Henschen. 
A. and Gonziilez-Rodriguez, J. (1989) Biochem. J. 261. 551-560 
[26] Laemmli, U.K. (1970) Nature 227. 680-685. 
[17] Towbin, H . Staehehn. T. and Gordon. J. (1979) Proc. Natl. 
Acad. SC]. USA 76, 43504354. 
[20] Kieffer, N., Bcnzard, B.. Didry. D.. Wautler. J.-L and Nurden, 
A.T. (1984) Blood 64, 1212~1219. 
[21] Goldberger. A, Kolodzlej, M.. Poncz, M., Bennett, J.S and 
Newman. P.J. (1991) Blood 78. 681-687. 
[22] Take. H.. Tomiyama. Y, Shlbata. Y., Furubayashl. T. Honda. 
S., Mizutam, H . Nishlura, T.. Tsubaklo. T. Kurdta. Y., Yo- 
nezawa, T. and Tarui, S. (1990) Br J Haematol 76. 395400. 
[23] Calvete. J.J. and GonzBlez-Rodriguez, J. (1986) Blochem J. 340. 
155-161. 
[28] Florman. H.M. and wassarman. P.M. (1985) Cell 41. 313-324. 
[39] Cahete, J J., Arias, J.. Alvarez, M V.. L6pez. M.M , Henschen, 
A and GonzBlez-Rodriguez. J.(1991) Blochem J. 273, 767-775. 
[30] Calvete. J.J.. Arias. J., Alvarez, M V. L6pez. M.M.. Henschen. 
A. and GonzBlez-Rodriguez. J. (1991) Blochem. J. 274,457-463 
[31] Calvete. J J.. Henschen. A and Gonzalez-Rodriguez. J. (1989) 
Blochem. J. 261. 561-568. 
[32] Loftus. J C.. Plow, E.F.. Frehnger III, A.L . D’Souza, S.E 1 
Dlwon. D , Lacy. J.. Sorge. J and Gmsberg, M.H. (1987) Proc 
Natl. Acad Scl. USA 84. 71 l&71 18. 
[33] Frehnger III. A L., Lam, C.-T, Plow. E.F. Smith. M.A.. Loftus, 
J C and Ginsberg, M.H (1988) J Blol. Chem. 263. 12397-12402 
34 
